Hvilken er prisen på Renascience Inc. (4889)

Prisen på Renascience Inc. (4889) er $8.49

Hva er markedsverdien på Renascience Inc. (4889)

Markedsverdien på Renascience Inc. (4889) er $117.03M

Renascience Inc. (4889) Utestående Aksjer

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.

År	Utestående aksjer	Endre
Ikke nok data for de angitte datoene.

År

Utestående aksjer

Endre

Ikke nok data for de angitte datoene.

Selskap	Utestående aksjer	Forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Moderna, Inc. MRNA.US	396.00M	-	US
CSL Limited CSL.AX	478.91M	-	AU
Lonza Group AG LONN.SW	-	-	CH

Selskap

Utestående aksjer

Forskjell

Land